Robert MacLaren, MB, ChB, DPhil, FRCOphth, FRCS, FACS, FMedSci, Professor of Ophthalmology, University of Oxford, provides an overview of the history and background of the Biogen choroideremia phase 3 gene therapy clinical trial, recently published findings, his plans for the future related to the study's outcomes, and answers questions related to the research.